(Q34455031)

2 August 2017

1 reference

title

Homocysteine and cardiovascular disease in diabetes mellitus. (English)

1 reference

2 August 2017

main subject

cardiovascular disease

1 reference

Audelin MC

1

1 reference

2 August 2017

Genest J Jr

series ordinal

2

1 reference

2 August 2017

publication date

1 December 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

159

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

497-511

1 reference

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Prediction of Coronary Heart Disease Using Risk Factor Categories

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Diabetes mellitus and coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Diabetes and cardiovascular risk factors: the Framingham study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres. The World Health Organisation Multinational Study of Vascular Disease in Diabetics. Diabetes Drafting Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: medical office assessment: Writing Group I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Plasma homocyst(e)ine levels in men with premature coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Hyperhomocyst(e)inemia. A common and easily reversible risk factor for occlusive atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Association between Plasma Homocysteine Concentrations and Extracranial Carotid-Artery Stenosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Homocysteine and coronary artery disease in French Canadian subjects: relation with vitamins B12, B6, pyridoxal phosphate, and folate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Serum total homocysteine and coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Higher plasma homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Relationship between plasma homocysteine, vitamin status and extracranial carotid-artery stenosis in the Framingham Study population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Plasma homocyst(e)ine levels and graded risk for myocardial infarction: findings in two populations at contrasting risk for coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Plasma homocyst(e)ine: a risk factor for arterial occlusive diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Plasma homocysteine levels and mortality in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Association between plasma homocysteine and extracranial carotid arterial disease in older persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Association between plasma homocysteine and coronary artery disease in older persons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Correlation between plasma homocyst(e)ine and aortic atherosclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Plasma homocysteine and cardiovascular disease mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Homocysteine levels and coronary heart disease in Syria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Preventing Coronary Heart Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Homocysteine and cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Homocysteine and atherothrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Moderate hyperhomocyst(e)inemia is associated with the presence of coronary artery disease and the severity of coronary atherosclerosis in Koreans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Serum total homocysteine and coronary heart disease: prospective study in middle aged men.

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Nonfasting Plasma Total Homocysteine Levels and Stroke Incidence in Elderly Persons: The Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

The metabolism of homocysteine: pathways and regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

7 January 2021

Homocysteine metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Genetic and nongenetic factors for moderate hyperhomocyst(e)inemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Three different methods for the determination of total homocysteine in plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from the NHLBI Family Heart Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

HOMOCYSTINURIA, THROMBOSIS, AND THE BLOOD-PLATELETS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Homocystinemia. Vascular injury and arterial thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Effect of homocysteine and homocystine on platelet and vascular arachidonic acid metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Oxidation of low-density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Lipid peroxidation in homocysteinaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Lipid peroxidation and susceptibility of low-density lipoprotein to in vitro oxidation in hyperhomocysteinaemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Homocysteine mediated endothelial cell toxicity and its amelioration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Relationships between homocysteine, factor VIIa, and thrombin generation in acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

A prospective study of plasma homocyst(e)ine and risk of ischemic stroke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Homocysteine and ischaemic heart disease in the Caerphilly cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

The effect of folic acid fortification on plasma folate and total homocysteine concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Human homocysteine catabolism: three major pathways and their relevance to development of arterial occlusive disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Net uptake of plasma homocysteine by the rat kidney in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Sulphur containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulphide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Accumulation of sulphur-containing amino acids including cysteine-homocysteine in patients on maintenance haemodialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: possible implications for prevention of vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Homocysteine in the plasma of renal transplant recipients: effects of cofactors for methionine metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Plasma protein-bound homocyst(e)ine in patients requiring chronic haemodialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Lack of association between plasma homocysteine levels and microangiopathy in type 1 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Hyperhomocysteinemia as a risk factor for cardiovascular disease in patients undergoing hemodialysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Hyperhomocysteinaemia: a significant risk factor for cardiovascular disease in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

The effect of reduced glomerular filtration rate on plasma total homocysteine concentration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: a matched case-control study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Fasting and post-methionine load homocyst(e)ine values are correlated with microalbuminuria and could contribute to worsening vascular damage in non-insulin-dependent diabetes mellitus patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Glycation products and the pathogenesis of diabetic complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

The mechanism of collagen cross-linking in diabetes: a puzzle nearing resolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Oxidative stress and diabetic vascular complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

The changing face of macrovascular disease in non-insulin-dependent diabetes mellitus: an epidemic in progress.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Oxidative stress and lipids in diabetes: a role in endothelium vasodilator dysfunction?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Lipid advanced glycosylation: pathway for lipid oxidation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Management of dyslipidemia in adults with diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

What cardiologists need to know about diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Microalbuminuria predicts the development of serum lipoprotein abnormalities favouring atherogenesis in newly diagnosed type 2 (non-insulin-dependent) diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Plasma homocysteine concentrations in patients with type 1 diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Effects of streptozotocin-induced diabetes and of insulin treatment on homocysteine metabolism in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Plasma homocysteine concentrations are regulated by acute hyperinsulinemia in nondiabetic but not type 2 diabetic subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Plasma homocysteine concentrations in Japanese patients with non-insulin-dependent diabetes mellitus: effect of parenteral methylcobalamin treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Disturbance of intestinal absorption following metformin therapy (observations on the mode of action of biguanides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Does metformin increase the serum total homocysteine level in non-insulin-dependent diabetes mellitus?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Hyperhomocysteinemia is a risk factor for coronary arteriosclerosis in Japanese patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Folate and Vitamin B 6 From Diet and Supplements in Relation to Risk of Coronary Heart Disease Among Women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Serum folate and risk for coronary heart disease: results from a cohort of US adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Vitamins B6, B12, and folate: association with plasma total homocysteine and risk of coronary atherosclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Low serum folate but normal homocysteine levels in patients with atherosclerotic vascular disease and matched healthy controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes : 5-year follow-up of the Hoorn Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Plasma homocysteine and all-cause mortality in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Lipid-lowering drugs and homocysteine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Lipid-lowering drugs and homocysteine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Serum homocysteine increases after therapy with fenofibrate or bezafibrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Implication of fibrate therapy for homocysteine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Fenofibrate raises plasma homocysteine levels in the fasted and fed states

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900531-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0021-9150(01)00531-7

1 reference

2 August 2017

1 reference